Cart
sales@molnova.com
Glucagon-like peptide 1 (1-37), human
CAS No. 87805-34-3
Glucagon-like peptide 1 (1-37), human( HuGLP-1 )
Catalog No. M29847 CAS No. 87805-34-3
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not enhance pancreatic insulin secretion.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGlucagon-like peptide 1 (1-37), human
-
NoteResearch use only, not for human use.
-
Brief DescriptionGlucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not enhance pancreatic insulin secretion.
-
DescriptionGlucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not enhance pancreatic insulin secretion.(In Vitro):Glucagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proglucagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4h exposure to mouse serum. GLP-1(1-37) is confirmed to be a highly potent agonist of the GLP-1 receptor (GLP-1R) by measuring the expression of the luciferase reporter gene expression in transiently transfected human embryonic kidney (HEK293) cells.(In Vivo):GLP-1(1–37) decreased glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group.
-
In VitroGlucagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proglucagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4h exposure to mouse serum. GLP-1(1-37) is confirmed to be a highly potent agonist of the GLP-1 receptor (GLP-1R) by measuring the expression of the luciferase reporter gene expression in transiently transfected human embryonic kidney (HEK293) cells.
-
In VivoGLP-1(1–37) decreased glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group.
-
SynonymsHuGLP-1
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGLP-1 receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number87805-34-3
-
Formula Weight4169.48
-
Molecular FormulaC186H275N51O59
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Zhao L, et al. Glucagon-like peptide-1(1-37) can enhance blood glucose homeostasis in mice. Regul Pept. 2012 Oct 10;178(1-3):1-5.
molnova catalog
related products
-
PF-06882961
PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06882961 shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat.
-
Taspoglutide
Taspoglutide is a glucagon-like peptide-1(GLP-1) agonist for treatment of type 2 diabetes.
-
GLP-1R modulator C5
GLP-1R modulator C5 is a small molecule GLP-1R orthosteric modulator that enhances GLP-1 binding to GLP-1R via transmembrane sites and can be used in the study of type II diabetes.
